Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring after Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Single Center Experience

Eva Rettinger, MD, Michael Merker, MD, Hermann Kreyenberg, PhD, Thomas Krenn, MD, Matthias Dürken, MD, Jörg Faber, MD PhD, Sabine Huenecke, PhD, Claudia Brehm, PhD, Melanie Bremm, PhD, Shahrzad Bakhtiar, MD, Andre Manfred Willasch, MD, Andrea Jarisch, MD, Jan Soerensen, MD, Thomas Klingebiel, Prof., Peter Bader

Blood (2014) 124 (21): 3953.

https://doi.org/10.1182/blood.V124.21.3953.3953

Published: 2014

Journal Articles

DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia.

Kathrin Bernt, MD, Jorg Faber, MD, PhD, Tina N Davis, Andrew Kung, MD, PhD, Scott Armstrong, MD, PhD

Blood (2009) 114 (22): 212.

https://doi.org/10.1182/blood.V114.22.212.212

Published: 2009

Journal Articles

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

Przemyslaw Juszczynski, MD, PhD, Scott J. Rodig, MD, PhD, Kunihiko Takeyama, MD, PhD, Jing Ouyang, PhD, Jorg Faber, MD, PhD, Scott Armstrong, MD, PhD, Jeffery L. Kutok, MD, PhD, Margaret A. Shipp, MD

Blood (2008) 112 (11): 2539.

https://doi.org/10.1182/blood.V112.11.2539.2539

Published: 2008

Journal Articles

The Myocyte Enhancer Factor 2C ( MEF2C ) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias.

Jorg Faber, MD, PhD, Andrei V. Krivstov, PhD, Matthew C. Stubbs, PhD, Marry van den Heuvel-Eibrink, MD, PhD, Andrew L. Kung, MD, PhD, Christian M. Zwaan, MD, PhD, Scott A. Armstrong, MD, PhD

Blood (2007) 110 (11): 58.

https://doi.org/10.1182/blood.V110.11.58.58

Published: 2007

Journal Articles

HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.

Jorg Faber, MD, PhD, Andrei V. Krivtsov, PhD, Matthew C. Stubbs, PhD, Renee Wright, Marry van den Heuvel-Eibrink, MD PhD, Andrew L. Kung, MD PhD, Christian M. Zwaan, MD PhD, Scott A. Armstrong, MD PhD

Blood (2006) 108 (11): 734.

https://doi.org/10.1182/blood.V108.11.734.734

Published: 2006

NARROW

Long-Term Outcome of Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring after Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Single Center Experience

DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia.

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

The Myocyte Enhancer Factor 2C ( MEF2C ) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias.

HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Long-Term Outcome of Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring after Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Single Center Experience

DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia.

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

The Myocyte Enhancer Factor 2C ( MEF2C ) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias.

HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only